Area of research
Oncology · Immunology
Research interest
Research focused on Ovarian cancer and Adverse effect, with related work in Ipilimumab, Quality (philosophy), Olaparib. Notable publications include 'Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy', 'Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048', and 'Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study'.
Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048.
Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy
PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma
Abstract 1677: Assays of conventional chemotherapeutics and targeted drugs for ovarian cancer using patient derived models